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ABSTRACT 
 
As the past decade barely dawned, a fundamentally novel view of cancer relating to 
signal transduction through intracellular hormones/growth factors and their 
subunits began to unfold. Further along, it gained additional substance with the 
advent of the interdisciplinary fields of particle biology and peptide strings which 
explain (onco)protein dynamics in spacetime, for instance insulin-driven sub- and 
trans-cellular carcinogenesis, by physical principles. Here, this new understanding is 
expanded to introduce the concept of "oncoprotein metastasis" preceding cancer cell 
spread and, thereby, a particular emphasis is placed on its potential role in the 
emergence of the pre-metastatic niche. Consistent with this perception, yet unlike 
currently advocated treatments that target cancer cells only, future antineoplastic 
strategies should aim to mimic natural tumor suppressors as well as involve both 
(morphologically) normal and malignant cells. If validated in human patients with 
advanced cancer disease, its otherwise frequently lethal course may be halted and 
reversed just in time. 
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A huge amount of experimental data 
relating to the problem of cancer 
metastasis has accumulated (1). By 
contrast, concepts providing a basic 
interpretation of these observations have 
been few. Here, a new scenario is put 
forward on the spreading of the neoplastic 
process across cells and tissues that may 
prove seminal both for our future 
understanding and treatment of 
malignancies. 
 Currently, three major views serve 
to explain both the emergence of cancer 
and its metastatic spread. One of these 
frameworks is the (cellular) oncogene 
theory developed by Michael Bishop and 
Harold Varmus along with Dominique 
Stehelin in the early 1970s and still 
prevailing to date (2). It assumes an 
overactivity of oncogenes (through gene 
amplification and/or mutation) being at 
the root of neoplastic transformation and 
cancer cell spread. 
Another mechanism proposed to 
initiate and expand primary tumors as well 
as trigger its associated metastasis is the 
loss of (individual) tumor suppressor 
activity, a proposal that, in its essence, can 
be traced back to Theodor Boveri as well as 
later on to Alfred Knudson´s two-hit 
hypothesis and is best exemplified by the 
first discovered tumor suppressor gene Rb 
(3,4). This tumor suppressor dysfunction 
that is thought to decisively contribute to 
carcinogenesis can occur at the level of the 
genes, but, at least as far as the key tumor 
suppressor retinoblastoma protein (RB) is 
concerned, is found even more frequently 
at the protein level in the form of post-
translational modifications (5). 
 Thirdly and in more recent years, 
chromosomal abnormalities resulting in 
aneuploidy have emerged as another 
important potential origin for cancer 
(metastasis), mainly through the work of 
Peter Duesberg and his associates (6). 
 Yet, genetic and chromosomal 
views of cancer are not entirely 
satisfactory. For instance, Richmond 
Prehn raised already in 1994 the question 
as to whether mutations found in some 
genes of cancer cells may be rather an 
epiphenomenon accompanying the 
(already initiated) neoplastic process than 
a causative event (7). Along the same lines, 
Judah Folkman and coworkers have also 
appealed to (additionally) go outside the 
cancer genome (8) to find broader 
answers, one direction being traced by his 
long-standing idea on tumor angiogenesis 
(9). Nevertheless, such example may be 
understood just as an incentive to embark 
upon a multidirectional conceptual 
journey beyond the genome that 
altogether should yield the ultimate 
solution to the cancer problem. 
 In this context, my peptide string 
theory (10-12) is likely to represent a 
significant addition. It rests upon the 
assumption according to which major 
biological processes concerning distinct, 
yet related proteins are the result both of 
(long-distance) attractive forces in the 
sense of the physical string theory (13,14) 
and of "emergent properties" inherent to 
the same proteins whereby the term 
Radulescu Sub-cellular cancer metastasis and its therapy arXiv December 18, 2007 
 - 3 - 
"emergent" is to be understood as 
employed by John Searle in his book 
entitled "The Mystery of Consciousness" 
where he illustrated it by explaining that 
single H2O molecules are not fluid by 
themselves, yet they create water when 
joining each other which is thus an 
"emergent" property of theirs. More 
specifically speaking, I have outlined how, 
for instance, the oncogenic information or 
message, respectively, encoded by certain 
peptide motifs in oncoproteins 
"propagates" within and across cells as a 
result of numerous interactions among 
(allosteric) proteins (silently or dormantly) 
harboring similar or identical motifs, 
hence yielding an "oncogenic state" in 
(normal as well as transformed) tissues 
and ultimately in an entire organism 
affected by a given cancer disease (11,12). 
From such (onco)peptide string 
view of cancer, it follows that, contrary to 
the current dogma of solely cancer cell-
targeted therapies (15), both normal and 
cancer cells should be treated, specifically 
aiming to globally disrupt the oncoprotein-
driven process that is not limited to 
individual (cancer) cell borders (16,17). 
This could be achieved by cell-permeable 
tumor suppressor peptides, particularly 
those using tumor-suppressive 
components of the RB pathway as a 
template, that enter both normal and 
cancer cells, as already suggested (18). 
At this point, it may be worthwhile 
considering the conceptual origins of my 
peptide string theory and its (anticipated) 
equivalents in the work of other 
investigators. Following my initial 
identification of the LXCXE RB-binding 
motif in the B-chain of human insulin in 
1992 (19), I predicted a physical 
interaction between insulin and RB as well 
as the involvement of this complex 
formation in embryogenesis and 
oncogenesis (19). I then generalized this 
potential phenomenon to postulate that 
the increased (post-translational) 
generation of hormone and growth factor 
subunits may contribute to (accelerated) 
tumor formation (20), thus bypassing 
lengthy cell membrane-to-nucleus signal 
transduction cascades and ensuing 
activations of various gene expression 
machineries. Furthermore, I surmised that 
there may exist also other examples 
besides insulin for such "nucleocrine" 
hormones and growth factors which, as I 
defined them by this term, directly bind 
nuclear tumor suppressors, thereby 
inactivate them and hence promote 
neoplastic transformation (21). 
In the course of this early work on 
the nuclear insulin-RB interaction as well 
as, more broadly speaking, on growth 
factors and/or their subunits "gravitating" 
towards the (cancer) cell nucleus, I 
realized in 1994 that some physical laws 
may particularly apply to carcinogenesis 
and summarized such thoughts in my 
particle biology theory published in 2003 
(22). This framework and particularly its 
intrinsic "bio-gravitation" and field 
concepts then served as a basis for the 
development of my peptide string theory 
which could be considered as a specific 
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candidate for the different law in physics 
postulated to exist in biology by Max 
Delbrück a long time ago.  
A key twist of this retrospective on 
the roots of my peptide string concept is 
the fact that I had already envisaged 
within my particle biology theory in 1994 
that oncogenic mechanisms- and 
subsequently also equivalent (epi)genetic 
changes- occur in morphologically normal 
cells during a given cancer disease as well 
as inferred (protein-based) fields 
transcending cellular boundaries (22). 
Consistent with this anticipation, Helene 
S. Smith et al. reported in 1996 that 
normal cells adjacent to a breast 
carcinoma bear neoplastic changes such as 
a loss of heterozygosity in some candidate 
tumor suppressor genes and thereby 
conjectured a potential "field effect" (23). 
Likewise, it was revealed by infrared 
spectroscopy that morphologically normal 
cells contiguous to neoplastic tissues 
display structural abnormalities (24) or, 
respectively, feature a cancer DNA 
phenotype (25). 
Consequently, if normal cells in a 
cancer patient contain such pre-malignant 
alterations, it would not be too far-fetched 
to assume that they also harbor (as yet 
undetermined or poorly determined) 
single protein modifications (such as a 
hyper-phosphorylation and thus  
inactivation of RB) and oncoprotein-tumor 
suppressor complexes that may predispose  
these cells to hyperproliferation and 
gradually also neoplastic transformation. 
In this context, the elevated 
(fasting) insulin blood levels or 
hyperinsulinemia, respectively, observed 
in some cancer patients (26-31) could be 
an important clinical hint to check for the 
above presumed protein-based 
phenomena in normal cells adjacent to a 
given carcinoma. More precisely stated, 
such abundance of circulating insulin may 
serve as one source among several (besides 
potential paracrine and autocrine ones) to 
fuel insulin for cellular internalization and 
nuclear translocation in many different 
tissues and, in turn, nuclear insulin could 
then bind and inactivate RB, as already 
shown (32). Considering further that this 
growth-promoting hormone is able to 
undergo a rapid transport across cells (33), 
those insulin molecules remained 
unbound to nuclear RB during a first 
oncoprotein invasion "wave" could 
proceed to enter and, due to their still 
excessive concentrations, transform other 
normal cells.  
These events could occur before 
any (epi)genetic and/or morphological 
changes have taken place in these cells, 
hence being even more in advance of the 
seed-and-soil process Stephen Paget had 
hypothesized already in the 19th century to 
involve individual cancer cells leaving the 
primary tumor for the bloodstream and, 
upon extravasation, settling down in 
distant tissue sites conducive to their 
thriving. Such proposed oncoprotein-
driven mechanism would crucially 
contribute to establishing the pre-
metastatic niche whose formation is a 
prerequisite for the invasion and 
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subsequent survival of metastatic cells 
arriving from far away. Conceivably, these 
"molecular preparations" could, however, 
only be completed in those tissues that are 
not capable of successfully mounting 
tumor-suppressive mechanisms, hence 
providing a novel dimension to explaining 
the clinically observed phenomenon 
according to which some primary tumors 
preferentially and visibly metastasize to 
certain sites in the body. Moreover, those 
cancer cells which have achieved to "land" 
in distant tissues  should accelerate the 
phenotypic conversion of their 
surrounding pre-malignant cells into overt 
tumor cells, e.g. through soluble factors 
they may secrete into their 
microenvironment. 
Essentially, the hyperinsulinemia 
of malignancy and its intracellular 
sequelae would altogether represent the 
paradigm for what I wish to coin as 
"oncoprotein metastasis" which, by my 
present definition, precedes cancer cell 
metastasis. In other words, the message 
carried by the insulin LXCXE motif and its 
spread across cells in the entire organism 
would epitomize a paramount oncogenic 
peptide string. 
If this scenario proved true, then 
the specific disruption of (intracellular) 
insulin-RB heterodimers through cell-
permeable RB-derived peptides (34-36)- 
that, by virtue of their structure, are not 
restricted to recognizing only malignant 
cells- could be one way for effectively 
treating cancer metastasis. Ultimately, this 
type of pharmacological agents could serve 
as a model for future therapies that do no 
longer target tumor cells alone to eradicate 
life-threatening metastasis, but instead 
anticipate and thus most likely disconnect 
it in time by installing a tumor-suppressive 
(anti-oncogenic peptide string) state in all 
cells, normal and cancerous alike. 
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